After about 5 years of Hepcludex it´s time to give a follow up on the experiences with the drug. In this episode we talk to the inventor of bulvertide, S. Urban (project leader in our TRR179) and a clinician expert (P. Lampertico from Milan).

We will refer to the following questions:

Which patients benefit from bulevirtide? What about HCC and decomp. cirrhosis?

Do we need interferon for best efficacy? Are the supply chains of interferon a problem?

What do we do with treatment failures? When is someone a treatment failure?

What else is there beyond bulevirtide?

What are the prospects for bulevirtide/entry inhibition in HBV monoinfection?